Abiopharma

🔍 Pauls Matthew (Director)

Company: Pelthos Therapeutics Inc. (PTHS)

Report Date: 2026-04-02

Detailed Transactions and Holdings:

• Sold 415 shares of Common Stock at $20.5154 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,521.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 371 shares of Common Stock at $21.3628 per share (Direct)
  Date: 2026-04-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,150.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
• F2: This transaction was executed in multiple trades at prices ranging from $20.30 to $20.78. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
• F3: This transaction was executed in multiple trades at prices ranging from $21.31 to $22.03. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.